Physician profile
Daniel T Burlon
NPI 1306882634
$11,405.47
in general payments reported to CMS, 2019-2025
42 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,634 · 2020: $1,323 · 2021: $1,712 · 2022: $1,424 · 2023: $1,780 · 2024: $1,848 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,313.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,570.49 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,242.23 | 2021-2025 | Qulipta, Linzess, Ubrelvy |
| Amgen INC. | $1,016.07 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $783.26 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $584.04 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $535.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $419.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $418.37 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Sumitomo Pharma America, INC. | $377.25 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $370.32 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.43 | 2019-2025 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $330.71 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $300.58 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $298.59 | 2019-2022 | |
| Pfizer INC. | $235.18 | 2019-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Burlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.